Cargando…
786. Effect of Nirmatrelvir/Ritonavir versus Placebo on COVID-19─Related Hospitalizations and Other Medical Visits
BACKGROUND: Nirmatrelvir coadministered with ritonavir (nirmatrelvir/r) is a COVID-19 treatment. This study evaluated nirmatrelvir/r in nonhospitalized, symptomatic adults with COVID-19 at high risk of progressing to severe disease. We report secondary efficacy endpoints associated with COVID-19─rel...
Autores principales: | Hammond, Jennifer, Leister-Tebbe, Heidi, Gardner, Annie, Abreu, Paula, Bao, Weihang, Wisemandle, Wayne, Ansari, Wajeeha, Simón Campos, Jesus Abraham, Pypstra, Rienk, Rusnak, James M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751968/ http://dx.doi.org/10.1093/ofid/ofac492.047 |
Ejemplares similares
-
532. Nirmatrelvir/Ritonavir Versus Placebo in Unvaccinated and Vaccinated High Risk Patients
por: Leister-Tebbe, Heidi, et al.
Publicado: (2023) -
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
por: Hammond, Jennifer, et al.
Publicado: (2022) -
Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
por: Anderson, Annaliesa S., et al.
Publicado: (2022) -
Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022) -
Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)